An analysis of implantable cardiac device reliability. The case for improved postmarketing risk assessment and surveillance.

Implantable cardiac devices have become the mainstay of the treatment of patients with heart disease. However, data regarding their reliability and, inferentially, safety have been called into question. We reviewed annual reports submitted to the Food and Drug Administration Office of Device Evaluat